HHS purchases IV antiviral drug to treat monkeypox
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the manufacturer expects to deliver next year. Under its contract with SIGA Technologies, HHS may still purchase additional oral and IV TPOXX, an antiviral drug approved by the Food and Drug Administration to treat smallpox and available under an investigational protocol to treat monkeypox. TPOXX is available free to states and territories through the Strategic National Stockpile, which held over 1.7 million treatment courses before the monkeypox outbreak. HHS last week declared the U.S. outbreak, which exceeds 10,000 cases, a public health emergency.
Related News Articles
Headline
The Food and Drug Administration Friday authorized for emergency use a molecular test to detect mpox (formerly known as monkeypox) at the point of care in…
Chairperson's File
March 12–18 is Patient Safety Awareness Week. While patient safety is a priority every day of the year for teams working at our nation’s hospitals and health…
Headline
The Food and Drug Administration Friday authorized for emergency use the first over-the-counter test to detect both flu and SARS-CoV-2, the virus that causes…
Headline
AHA’s United Against the Flu campaign today released a new social media toolkit to help hospitals and health systems encourage their communities to get…
Headline
The Food and Drug Administration Friday authorized for emergency use a real-time polymerase chain reaction test to detect mpox (formerly known as…
Headline
The Society for Healthcare Epidemiology, in collaboration with AHA and other organizations, yesterday published updated best practices for hospitals to…